It has been known for some time that the bacterium, Pseudomonas aeruginosa, grows within the deadly, lung-clogging mucous found in the airways of cystic fibrosis patients and significantly weakens them.

A new study suggests, however, that a mutation -- known as mucA -- in the organism also represents a fatal flaw that could help physicians clear the characteristic "goop" from the lungs of advanced cystic fibrosis patients.

The reason for optimism, the researchers say, is that the same genetic change that turns Pseudomonas aeruginosa into a sticky, antibiotic-resistant killer also leaves it susceptible to destruction by slightly acidified sodium nitrite, a common chemical that is widely used in the curing of lunch meat, sausages and bacon.

The finding is reported in the Journal of Clinical Investigation by a 15-member U.S. and Canadian team headed by Daniel Hassett, at University of Cincinnati.

" We believe that we have discovered the Achilles' heel of the formidable mucoid form of Pseudomonas aeruginosa, which could lead to improved treatment for cystic fibrosis airway disease," said Hassett. " We can essentially say that this organism, which some people thought could never be beaten, can now be destroyed by nothing more exotic than a common food preservative."

Cystic fibrosis, which affects about 30,000 people in the United States, mostly Caucasians of north European origin, is an inherited disease caused by a defect in a gene called the cystic fibrosis transmembrane conductance regulator ( CFTR ).
Affecting the airways and many other vital organs and processes, cystic fibrosis is chronic, progressive and ultimately fatal, mostly as a result of respiratory failure.

" The lung-clogging, suffocating mucoid form of Pseudomonas aeruginosa essentially is a death sentence for cystic fibrosis patients because these bacteria are inherently antibiotic and white-cell resistant," said Hassett.

Until the 1980s, most deaths from cystic fibrosis occurred in children and teenagers. Today, thanks to improved treatments, people with cystic fibrosis live an average of 35 years.

" During the chronic form of cystic fibrosis, " Hassett said, " the mutated form of the organism, combined with the immune system's attempts to fight it off, wreaks havoc in the lungs.

" When Pseudomonas aeruginosa invades the mucous that's built up in the airways," said Hassett, " it forms a resistant ' biofilm, ' like that which occurs on teeth or a toilet bowl, and divides rapidly.

" White cells from our immune system try to get in there to fight off the invaders," he added, " but they can't reach the bacteria to kill them because they're enmeshed in that thick mucous, essentially a human form of 'quicksand.' So in trying to defend the body against the Pseudomonas aeruginosa, the white blood cells end up dumping toxic, damaging material onto the airway surfaces, which leads to lung destruction.

" This biofilm lines the whole area, getting thicker and thicker and developing into a dense layer that deprives surface tissue of oxygen, ultimately killing it. So it's not only the bacteria that contribute to the disease, it's also our own immune system."

Hassett and his colleagues found that about 87 percent of the mucoid Pseudomonas organisms they studied have a " fatal flaw " in the very gene ( mucA ) that makes it mucoid as well as antibiotic and immune-system resistant -- they are easily destroyed by slightly acidified ( pH 6.5 ) sodium nitrite.

Part of the problem with early and chronic cystic fibrosis, Hassett explained, is that patients with these conditions make very little nitric oxide, a derivative of acidified sodium nitrite.

" Mucoid Pseudomonas aeruginosa bacteria should have enzymes that are able to dispose of both nitrite and nitric oxide," Hassett said, " but for whatever reason, this particular bug doesn't make them, or has very low levels of them.

" That's the fatal flaw in mucoid Pseudomonas aeruginosa."

Hassett and his colleagues had worked on the hypothesis that the mucoid bacteria -- because they flourish in patients who are essentially drowning in their own airway mucous -- would grow better using nitrate or nitrite as an alternative to the missing oxygen. But when they tested nonmucoid and mucoid forms, the nonmucoids grew with both nitrate and nitrite without oxygen, while the mucoid organism grew only with nitrate, yet died with nitrite.

The team took about 60 mucoid bacteria from six different clinics in the United States and Canada and found that of all the strains that were mucoid, the ones that had mucA mutations were all sensitive to nitrite, and those that are notoriously antibiotic resistant were even more sensitive.

" Sodium nitrite kills the mucoids, and if nonmucoids or other bacteria are present in the airways, it inhibits their growth too," said Hassett.

" When we add slightly acidified sodium nitrite to a suspension containing mucoid bacteria, it's converted to the gas nitric oxide," said Hassett. " The mucoid bacteria can't dispose of the nitrite metabolically, and also have difficulty handling the gas, so they die.

" Here was something we hypothesized that would allow mucoid bacteria to grow much better than nonmucoid bacteria, but instead it killed them," said Hassett. " In plain English, these bacteria had a defect that we didn't anticipate. I've never been so happy in my life to be wrong! "

Sodium nitrite, Hassett said, has potential as "a time-release" capsule for cystic fibrosis patients. Because the nitrite is degraded very slowly, and mucoid bacteria can't get rid of it, it should specifically kill mucoid organisms that have the mucA mutation -- which most do.

Hassett said he envisions sodium nitrite could be used in aerosol form to treat mucoid Pseudomonas aeruginosa in cystic fibrosis lung disease.

" This wouldn't need to be a long-term treatment," he said. " Once a patient acquires mucoids, which commonly occur, the physician would simply use sodium nitrite and monitor how many mucoid bacteria are still in airway sputum. Once the mucoid organisms are killed, and the patient starts showing signs of improvement, treatment would continue with conventional antibiotics."

Source: University of Cincinnati, 2006


XagenaMedicine2006